3 research outputs found
Experience with the use of Rituximab for the treatment of rheumatoid arthritis in a tertiary Hospital in Spain: RITAR study
There is evidence supporting that there are no
relevant clinical differences between dosing rituximab 1000 mg or 2000 mg
per cycle in rheumatoid arthritis (RA) patients in clinical trials, and low-dose
cycles seem to have a better safety profile. Our objective was to describe the
pattern of use of rituximab in real-life practice conditions.
Methods: Rituximab for RA in clinical practice (RITAR) study is a retrospective cohort study from 2005 to 2015. Eligibility criteria were RA adults
treated with rituximab for active articular disease. Response duration was
the main outcome defined as months elapsed from the date of rituximab
first infusion to the date of flare. A multivariable analysis was performed
to determine the variables associated with response duration.
Results: A total of 114 patients and 409 cycles were described, 93.0%
seropositive and 80.7% women. Rituximab was mainly used as second-line
biological therapy. On demand retreatment was used in 94.6% of cases
versus fixed 6 months retreatment in 5.4%. Median response duration
to on demand rituximab cycles was 10 months (interquartile range,
7–13). Multivariable analysis showed that age older than 65 years, number
of rituximab cycles, seropositivity, and first- or second-line therapy were
associated with longer response duration. The dose administered at each
cycle was not significantly associated with response duration.
Conclusions: Our experience suggests that 1000 mg rituximab single infusion on demand is a reasonable schedule for long-term treatment of those
patients with good response after the first cycles, especially in seropositive
patients and when it is applied as a first- or second-line biological therap
Implicación de las células sinoviales en la patogenía de la poliartritis inducida
Tesis doctoral original inédita leída en la Universidad de Autónoma de Madrid, Facultad de Medicina. Fecha de lectura: 12 de diciembre de 198